Literature DB >> 17207379

Interleukin-1 receptor antagonist (IL-1RN) and interleukin-1B gene polymorphisms in Turkish patients with rheumatoid arthritis.

A Arman1, B Yilmaz, A Coker, N Inanc, H Direskeneli.   

Abstract

OBJECTIVE: Interleukin 1 (IL-1) family is composed of two agonists, IL-1alpha and IL-1Beta and IL-1 receptor antagonist, IL-1Ra. The purpose of this study was to determine the relationship between polymorphisms of IL-1 receptor antagonist (IL-1RN), IL-1B promoter and IL-1B exon 5 genes and susceptibility to rheumatoid arthritis (RA) in Turkish population.
METHODS: Polymerase chain reaction (PCR) was used to determine the genotype of the IL-1RN for 94 RA patients and 104 healthy controls. Genotyping of IL-1B polymorphisms at positions -511 (C/T) and +3953 (C/T) was detected by PCR followed restriction fragment length analysis.
RESULTS: There was no significant difference in IL-1RN genotype and allele distributions between RA and the control groups. In addition, no significant association was observed in the allelic frequency (C or T) of IL-1B promoter (-511) between RA patients and the controls (P = 0,118), but the genotype distribution of 1/2 (C/T) at position -511 showed a significant difference (P = 0,038). Also, 2/2 genotype (T/T); (P = 0,028), and allele 2 (T) distribution (P = 0,011) of IL-1B (+3953) showed significant differences between RA patients and the control groups in the study population.
CONCLUSION: These results imply that 2/2 (T/T) genotype or allele 2 (T) of IL-B (+3953) are susceptibility factors for RA in Turkey. Also, 1/2 genotype (C/T) of IL-1 -511 can play a protective role for RA.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17207379

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  7 in total

1.  Association of 86 bp variable number of tandem repeat (VNTR) polymorphism of interleukin-1 receptor antagonist (IL1RN) with susceptibility and clinical activity in rheumatoid arthritis.

Authors:  S Ramírez-Pérez; M Salazar-Páramo; S Pineda-Monjarás; U De la Cruz-Mosso; J Hernández-Bello; G E Martínez-Bonilla; A L Pereira-Suárez; J F Muñoz-Valle
Journal:  Clin Rheumatol       Date:  2017-03-25       Impact factor: 2.980

2.  Pro-inflammatory cytokine response pre-dominates immuno-genetic pathway in development of rheumatoid arthritis.

Authors:  E K Krishna Priya; Lekshmy Srinivas; S Rajesh; Kesavarao Sasikala; Moinak Banerjee
Journal:  Mol Biol Rep       Date:  2020-10-19       Impact factor: 2.316

Review 3.  Interleukins and interleukin receptors in rheumatoid arthritis: Research, diagnostics and clinical implications.

Authors:  Lili Magyari; Dalma Varszegi; Erzsebet Kovesdi; Patricia Sarlos; Bernadett Farago; Andras Javorhazy; Katalin Sumegi; Zsolt Banfai; Bela Melegh
Journal:  World J Orthop       Date:  2014-09-18

4.  IL1RN*2 allele of IL-1receptor antagonist VNTR polymorphism is associated with susceptibility to ankylosing [corrected] spondylitis in Indian patients.

Authors:  Sumeet Agrawal; Rajni Srivastava; Banwari Sharma; Sapan Pandya; Ramnath Misra; Amita Aggarwal
Journal:  Clin Rheumatol       Date:  2007-09-27       Impact factor: 2.980

5.  The Clinical Significance of Interleukin-1 Receptor Antagonist +2018 Polymorphism in Rheumatoid Arthritis.

Authors:  Endom Ismail; Omimah Khaled Jaber Nofal; Rajalingham Sakthiswary; Syahrul Sazliyana Shaharir; Radhika Sridharan
Journal:  PLoS One       Date:  2016-04-22       Impact factor: 3.240

Review 6.  Proinflammatory Cytokines (IL-1, -6, -8, -15, -17, -18, -23, TNF-α) Single Nucleotide Polymorphisms in Rheumatoid Arthritis-A Literature Review.

Authors:  Olga M Koper-Lenkiewicz; Kinga Sutkowska; Natalia Wawrusiewicz-Kurylonek; Ewa Kowalewska; Joanna Matowicka-Karna
Journal:  Int J Mol Sci       Date:  2022-02-14       Impact factor: 5.923

Review 7.  Pharmacogenomics of Monoclonal Antibodies for the Treatment of Rheumatoid Arthritis.

Authors:  Sung Ho Lim; Khangyoo Kim; Chang-Ik Choi
Journal:  J Pers Med       Date:  2022-07-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.